Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label study

Abstract Marginal zone lymphoma (MZL) is an indolent type of non‐Hodgkin lymphoma that develops through pathological B cell receptor signaling. Orelabrutinib, a new‐generation oral small molecule Bruton's tyrosine kinase inhibitor, was evaluated in relapsed/refractory (r/r) MZL patients. Previously treated r/r MZL patients received orelabrutinib 150 mg once daily in a phase 2, multicenter, single‐arm study conducted in China. The primary endpoint was overall response rate (ORR) assessed by an Independent Review Committee (IRC) based on the Lugano 2014 classification. Other efficacy, safety, and pharmacokinetic profiles were evaluated as secondary outcome measures. A total of 111 patients were enrolled, of which 90 patients had MZL confirmed by central pathology review, who were mainly with extra‐nodal MZL of mucosa‐associated lymphoid tissue (MALT, 46.7%) and nodal MZL (35.6%). The majority had late‐stage disease, with stage IV accounting for 75.6%. After a median follow‐up duration of 24.3 months, the IRC‐assessed ORR was 58.9% (95% confidence interval [CI], 48.0–69.2), with rates of complete response and partial response being 11.1% and 47.8%, respectively. The IRC‐assessed median duration of response was 34.3 months, and the IRC‐assessed median progression‐free survival (PFS) was not reached with a 12‐month PFS rate of 82.8% (95% CI, 72.6–89.5). The rate of overall survival at 12 months was 91.0% (95% CI, 82.8–95.4). Common all‐grade treatment‐related adverse events (TRAEs) included anemia (27.9%), neutrophil count decrease (23.4%), white blood cell count decrease (18.0%), platelet count decrease (17.1%), blood present in urine (16.2%), rash (14.4%), and upper respiratory tract infection (10.8%). Thirty‐four patients (30.6%) experienced grade 3 or higher TRAEs. Serious TRAEs occurred in 18 patients (16.2%), of which pneumonia (5.4%) was the most common. Seven patients (6.3%) discontinued orelabrutinib due to TRAEs. Orelabrutinib demonstrated high response rates with durable disease remission and was well tolerated in Chinese patients with r/r MZL.